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Abstract: The relatively high post-treatment relapse rates of paromomycin (PMM) in visceral leish-
maniasis treatment and the swift emergence of experimental drug resistance challenge its broad
application and urge for rational use and monitoring of resistance. However, no causal molecular
mechanisms to Leishmania PMM resistance have been identified so far. To gain insights into potential
resistance mechanisms, twelve experimentally selected Leishmania donovani clonal lines and the non-
cloned preselection population, with variable degrees of PMM resistance, were subjected to whole
genome sequencing. To identify genomic variations potentially associated with resistance, SNPs,
Indels, chromosomal somy and gene copy number variations were compared between the different
parasite lines. A total of 11 short nucleotide variations and the copy number alterations in 39 genes
were correlated to PMM resistance. Some of the identified genes are involved in transcription, trans-
lation and protein turn-over (transcription elongation factor-like protein, RNA-binding protein, ribosomal
protein L1a, 60S ribosomal protein L6, eukaryotic translation initiation factor 4E-1, proteasome regulatory
non-ATP-ase subunit 3), virulence (major surface protease gp63, protein-tyrosine phosphatase 1-like protein),
mitochondrial function (ADP/ATP mitochondrial carrier-like protein), signaling (phosphatidylinositol
3-related kinase, protein kinase putative and protein-tyrosine phosphatase 1-like protein) and vesicular
trafficking (ras-related protein RAB1). These results indicate that, in Leishmania, the aminoglycoside
PMM affects protein translational processes and underlines the complex and probably multifactorial
origin of resistance.
Keywords: paromomycin; resistance; sequencing; SNP; CNV
1. Introduction
Leishmania parasites belong to the family of Trypanosomatidae and are unicellular
flagellates that are transmitted between different vertebrates via the bites of infected sand
flies. Depending on the species, Leishmania can cause either cutaneous (CL), mucocutaneous
(MCL) or visceral leishmaniasis (VL). These parasites are known for their high plasticity
and rapid adaptation to different environmental conditions, such as drug exposure [1].
The efficacy of the aminoglycoside antibiotic paromomycin (PMM) against both CL
and VL has been demonstrated in monotherapy and in combination with other anti-
leishmanials, with cure rates up to 80% [2–6]. The relatively high post-treatment relapse
rates challenge the broad application of PMM in VL treatment, and urge for rational use
and monitoring of the emergence of resistance [7], particularly because several in vitro
and in vivo laboratory studies demonstrated fairly easy selection of resistance both on
promastigotes and intracellular amastigotes [8–11]. A stepwise increase of PMM pressure
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onto promastigotes led to a decreased PMM susceptibility of both stages, whereas exposure
of intracellular amastigotes in vitro or in vivo resulted in an amastigote-specific increase
of PMM IC50 [9]. This stage-dependent outcome disfavors the use of the promastigote
stage for primary resistance monitoring and emphasizes the need for resistance markers
to monitor the emergence and spread of PMM resistance in the field [9]. With the aim
to discover putative PMM resistance markers and molecular mechanisms enrolled in
PMM resistance, whole genome sequences of experimentally amastigote-selected clones
with different levels of PMM susceptibility were compared among each other and to the
wild-type (WT) drug-susceptible parent strain. This led to the identification of short-
nucleotide variants (SNVs) and gene expansion/deletions that could be associated with
PMM resistance.
2. Materials and Methods
Promastigotes of L. donovani MHOM/NP/03/BPK275/0-cl18, isolated within the
frame of the EC Kaladrug-R project from a patient not responding to treatment with sodium
stibogluconate, were sub-cultured twice weekly in HOMEM promastigote medium (Life
technologies, Ghent, Belgium) at 25 ◦C. Resistance was selected in vitro on intracellular
amastigotes, as previously described [9,12]. Twelve clonal isolates were obtained from
the resulting polyclonal-resistant population (Table 1). The PMM and miltefosine (MIL)
susceptibility of intracellular amastigotes was determined for each clone and the non-cloned
population, as described previously [8]. In addition, their susceptibility to amphotericin
B (AmB; Sigma Aldrich, Overijse, Belgium) was calculated to evaluate potential cross-
resistance.
Table 1. Intracellular amastigote IC50 values of the pre-selection population and the 12 different
post-selection clones against paromomycin (PMM) and amphotericin B (AmB). Results are expressed
as the average IC50 (in µM) ± the standard error of the mean (SEM). The clones that were considered
resistant (resistance index (RI) > 5) are indicated in bold. Those considered susceptible (RI < 2) are
indicated in italics. All reported IC50 values are the result of at least two independent experiments
run in duplicate.
Strain PMM IC50 (µM)
1 AmB IC50 (nM)
Wild-type (preselection) 45.0 ± 5.6 9.7 ± 0.2
Clone 1 417.4 ± 15.1 20.9 ± 6.6
Clone 2 196.8 ±11.2 15.4 ± 2.0
Clone 3 213.0 ± 7.3 19.6 ± 4.5
Clone 4 157.0 ± 9.6 22.4 ± 6.1
Clone 5 129.7 ± 13.1 10.5 ± 1.0
Clone 6 57.1 ± 6.8 11.8 ± 2.1
Clone 7 154.0 ± 14.9 22.0 ± 5.1
Clone 8 313.1 ± 14.3 15.3 ± 0.9
Clone 9 132.5 ± 9.0 13.8 ± 0.8
Clone 12 171.3 ± 5.7 13.7 ± 1.7
Clone 13 310.2 ± 11.8 17.0 ± 3.5
Clone 14 71.2 ± 2.8 ND
1 These results have already been published elsewhere [9]. ND: Not done.
Promastigotes from twelve clones and the non-cloned population in exponential
growth phase were used for DNA extraction by the QIAamp DNA Mini Kit according to
the manufacturer’s instructions (Qiagen, Antwerp, Belgium). Genomic DNA was used
to generate paired-end libraries using the NEBNext Ultra II FS DNA library prep kit
for Illumina sequencing (New England Biolabs, Ipswich, MA, USA), according to the
manufacturer’s protocol, and amplified using NEBNext multiplex oligos for Illumina (dual
index primers, New England Biolabs). Pooled and barcoded libraries were sequenced to
2 × 150 bp on an Illumina Hiseq 3000 platform. Reads were mapped to the L. donovani
BPK282A1 genome version 39 available from TriTrypDB using BWA mem [13,14]. The
genome coverage was estimated based on the mean read depth of genes with non-outlier
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depth coverages for each isolate, using BEDtools genomecov version 2.27.1 (BEDTools,
version 2.27.1; A suite of utilities for comparing genomic features; Aaron Quinlan and Ira
Hall; Bioinformatics: University of Oxford, Oxford, England 2010) [15] and GFF coordinates.
Detailed descriptions of each read library are summarized in Supplementary Table S1.
Short-nucleotide variant (SNV) distribution and allele frequency variation among
L. donovani isolates were used to estimate populational diversity and potential associa-
tion of mutations with PMM resistance. SNVs were identified with a focus on single-
nucleotide polymorphism (SNPs) and short insertion–deletion mutations (INDELS). Calls
for each sample were generated with FreeBayes version 1.2.0 (FreeBayes, version 1.2.0;
Haplotype-based variant detection from short-read sequencing; Eric Garrison and Ga-
bor Marth; arXiv:1207.3907; 2012) [16], calling only on positions where the depth was at
least 5 reads. SNVs were filtered by: quality > 2000, minimum global allele frequency
(MAF) > 0.05, number of different alleles = 1, mapping quality and base quality of the
reference and alternate allele > 40, and proportion of observed reference and alternate
alleles which were supported by properly paired read fragments > 0.9, using VCFtools
version 0.1.16 (VCFtools, version 0.1.16; The variant call format and VCFtools; Adam
Auton, Petr Danecek and Anthony Marcketta; Bioinformatics: University of Oxford, Ox-
ford, England 2011) [17] and BCFtools version 1.10.2 (BCFtools, version 1.10.2; Utilities
for variant calling and manipulation VCFs and BCFs; Heng Li; Bioinformatics: University
of Oxford, Oxford, England 2011) [18]. To identify SNVs that occurred during selection
for PMM resistance, from the total of 7448 SNVs, we excluded the 5400 variants that
presented MAF < 0.05 or low-quality calls, representing unreliable calls or variants that
were present in all isolates, as these are simply differences between the isolates and the
reference assembly. The sharing of SNV positions among the 13 isolates was estimated
using BCFtools isec, and plotted in R using ggplot2. The populational genetic diversity (π)
was estimated with VCFtools window-pi, in 50 kb windows. The images of the diversity
values of these windows along the 36 L. donovani chromosomes were generated in R, us-
ing ggplot2 (https://cran.r-project.org/web/packages/ggplot2/index.html; accessed on
19 July 2021).
To estimate fluctuation in the ‘within-clone allele frequency’ for each SNV, the fre-
quency of the alternate allele was estimated by dividing the read depth of the alternate allele
by the total number of reads that mapped in the position. The heatmap representing the
fluctuations in alternate allele frequency along the chromosomes was generated in R, with
the heatmap2 function, from the gplots library (https://cran.r-project.org/web/packages/
gplots/index.html; accessed on 19 July 2021). L. donovani isolates were clustered based
on the Manhattan distance of the allele frequency of all SNVs, by UPGMA (unweighted
pair group method with arithmetic mean). SNV positions were drawn according to their
chromosomal positions, or reordered based on clustering by UPGMA of their Manhattan
distance. The genome-wide distribution density of the alternate allele frequencies of each
L. donovani sequenced isolate was estimated in R, with the density function, and used to
infer the parasite ploidy.
The potential impact of fluctuation in allele frequency of each SNV with PMM resis-
tance was estimated by the Pearson correlation of the allele frequency and the isolate PMM
IC50, in R, and the images were generated with ggplot2.
To evaluate the impact of gene and chromosomal copy alterations on PMM resistance,
the copies of all L. donovani 8135 genes and 36 chromosomes were estimated for the
12 sequenced clonal lines and the non-cloned population, and compared with their PMM
resistance profiles. To estimate gene copy numbers, the median read depth of each gene
was calculated with BEDtools genomecov version 2.27.1 (BEDTools, version 2.27.1; a suite
of utilities for comparing genomic features; Aaron Quinlan and Ira Hall; Bioinformatics:
University of Oxford, Oxford, England 2010), using gene coordinates from L. donovani
GFF version 39 from TriTrypDB. Read depths were transformed to relative copy number
values (copies per haploid genome copies) by dividing the gene coverages by the genome
coverage, estimated as the median coverage of non-outlier genes (Grubb’s tests, with
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p < 0.05). The somy of each chromosome from each L. donovani clone was estimated based
in the median coverage of non-outlier genes, as described by Reis-Cunha et al. [19]. Briefly,
mapped reads were filtered by mapping quality 30 using SAMtools version 1.10 (SAMtools,
version 1.10; Suite of programs for interacting with high-throughput sequencing data;
Heng Li; Bioinformatics: University of Oxford, Oxford, England 2009) [20] and genes
with outlier coverages were excluded, based on iterative Grubb’s tests, with p < 0.05.
The median read depth of all non-outlier genes in each chromosome was normalized by
the genome coverage and considered as the chromosomal somy. The potential impact
of each L. donovani gene copy number and chromosome somies on PMM resistance was
estimated by Pearson correlation of the gene copy number or somy against clone PMM
IC50 values. All statistical analyses were carried out using R v3.6.2 (R, version 3.6.2; The R
project for Statistical Computing; R core team; Vienna, Austria, 2019) [21], and graphical
representations were generated with ggplot2 [22].
3. Results
3.1. Amastigote Susceptibilty to Paromomycin and Amphotericin B
As described elsewhere [8], all in vitro selected clones showed lower susceptibility
to PMM than the parent strain, in several cases achieving 5–10-fold IC50 values (Table 1).
To evaluate potential cross-resistance to other drugs, the intracellular drug susceptibility
to amphotericin B was determined (Table 1). The in vitro susceptibility of this naturally
antimony-resistant strain against pentavalent and trivalent antimonials remained unaltered,
as did the susceptibility against MIL [9]. PMM and amphotericin B susceptibility were not
significantly correlated, which reinforces that the developed PMM resistance is specific to
this drug, and not a result of generic drug resistance mechanisms.
3.2. SNPs and Indels
We detected 7448 single-nucleotide variants (SNV), where 2048 (1222 single-nucleotide
polymorphisms (SNP) and 826 indel positions) vary among the evaluated Leishmania
isolates (Supplementary Table S1). Overall, the majority of these positions were present in
all post-selection clones (Figure 1a,b), which is expected given their similar origin. When
looking at the genetic diversity (π) between the different clones and the pre-selection
sample (Supplementary Figure S1), chromosomes 6, 12 and 34 (mostly euploid) and
chromosome 31 (aneuploid) had relatively high π spikes, which were generally a result
of co-localization of SNPs and indels (Figure 1c). Even though the SNV positions were
generally shared amongst most post-selection clones, variations in within-clone allele
frequency patterns were observed (Figure 2). These inconsistent counts of reads from the
two alleles may be due to gene duplications/losses. Therefore, SNVs in these clones were
further compared at the allele frequency level in the downstream analyses. It is noteworthy
that the genome-wide within-clone allele frequency patterns suggest that the progenitor
isolate was triploid, as are all post-selection clones. We expect that the variation in within-
clone allele frequencies is due to loss of heterozygosity due to fluctuating ploidy [23,24]
and/or the difficulty in estimating true allele counts in a triploid sample.
To identify SNVs that associate with PMM resistance, we have compared within-
clone allele frequencies to PMM IC50 values. A total of 11 SNV positions were correlated
with PMM resistance, from which 9 were located in intergenic regions and 2 resulted
in synonymous mutations (Figure 3, Supplementary Figures S2 and S3). These SNVs
were not clustered in close chromosomal regions and were dispersed over different re-
gions and chromosomes. The intergenic SNPs on chromosomes 18 and 35 showed the
strongest correlations with resistance and are located upstream of the chaperone DnaJ
protein (LdBPK_181410.1) and aspartate aminotransferase genes (LdBPK_350840.1). The
2 SNPs resulting in synonymous mutations were found in genes LdBPK_020680.1 (ATP-
dependent Clp protease subunit, heat-shock protein 78 (HSP78)) and LdBPK_362510.1 (sterol
24-c-methyltransferase) (Supplementary Table S2). For both genes, a negative correlation
was found between the alternate allele frequency and PMM resistance, suggesting that loss
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of the alternate alleles towards a reference-homozygous genotype correlates with PMM
resistance. The synonymous SNP in LdBPK_020680.1 (UCG → UCC) results in a lower
relative synonymous codon usage of the alternate codon (RSCU decrease from 1.439 to
1.115). For the sterol 24-c-methyltransferase, the synonymous mutation results in a higher




Figure 1. Genetic variability of the L donovani clones: (a) Number of SNV positions that are shared between exactly 1 to
12 clones and the polyclonal population. The Y and X axis represent, respectively, the number of variants and the exact
number of isolates in which the variant position was observed. A total of 84% of the SNV positions were present in all
clones and the non-cloned population. (b) Number of SNPs and indels in each chromosome. (c) Genetic diversity ( ) in
chromosomes 6, 12, 31 and 34 estimated using 50 kb windows. The Y and X axis represent, respectively, genetic diversity
and chromosomal position. SNVs, indels and SNPs are represented in red, blue and green, respectively.
3.3. Chromosomal Copy Number Variation (CCNV)
Of the 36 L. donovani chromosomes, two had significant correlations between chro-
mosome expansion and PMM resistance, Chr33 (r = 0.64, p-value = 0.02) and Chr34
(r = 0.56, p-value = 0.04) (Supplementary Figure S4). However, the correlation, r, was
lower than 0.7 and the amplitude of variation in these chromosome copies was low (Chr33,
minimum = 1.29, maximum = 1.39; Chr34, minimum = 0.89, maximum = 0.94). Within
their complex pattern of CCNV, the “chromosomal copy number drift” that could be ob-
served for all of the clones (Supplementary Figure S5) might be potentially explained by
adaptation to in vitro culture [26,27].
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Figure 2. SNVs alternate allele frequency variability. Alternate allele frequency of each SNV position in the L donovani clones
and preselection population. (a) SNVs ordered by chromosome position. The columns and lines correspond respectively to
SNV positions and the various L donovani clones. The allele frequency of the alternate allele is represented in a scale from
blue (low) to red (high). The dendrogram on the right represents the UPGMA clustering of the Manhattan distance of the
alternate allele frequencies. The color strip beside the dendrogram represents the PMM resistance phenotype, where RI < 2,
2 > RI > 5 and RI > 5 are represented respectively, in yellow, grey and purple. The order of the isolates, from top to bottom,
is: “preselection”, “CL 12”,“CL 1”,“CL 8”,“CL 13”,“CL 2”,“CL 14”,“CL 5”,“CL 7”,“CL 6”,“CL 4”,“CL 9” and “CL 13”. The
alternating light/dark green color strip on the top represents the chromosomes 1–36. (b) The SNVs columns were reordered
by UPGMA clustering of the Manhattan distance, instead of being ordered by chromosome position. (c) Genome-wide
density plot of the alternate allele frequency distribution of SNVs in the 12 clones and the preselection population. The X
and Y axis represent, respectively, the alternate allele frequency (from 0 to 1) and the allele frequency rate. The red dashed
line represents an alternate allele frequency of 0.5, the expected value for disomic chromosomes. The observed distribution
is suggestive of triploidy. (d) Median genome-wide allele frequency for each clone and the preselection population (Pre).
3.4. Gene Copy Number Variations (CNV)
A significant correlation could be noted between PMM resistance and an increased
or decreased gene copy number of 33 and 6 genes, respectively (Figure 4, Supplementary
Figures S3 and S6). The genes with the highest correlation to PMM resistance are summa-
rized in Table 2. The gene with the largest difference between the maximum and minimum
gene copy values is a small hypothetical protein (LdBPK_020370.1), with no identifiable
functional motifs. Although 14 genes are hypothetical genes, the other 25 are putatively
enrolled in several functions, such as: transcription, translation and protein turn-over
(transcription elongation factor-like protein, RNA-binding protein, ribosomal protein L1a, 60S ribo-
somal protein L6, eukaryotic translation initiation factor 4E-1, proteasome regulatory non-ATP-ase
subunit 3 and RING-H2 zinc finger, with possible involvement in protein ubiquitination), vir-
ulence (major surface protease gp63, protein-tyrosine phosphatase 1-like protein), mitochondrial
function (ADP/ATP mitochondrial carrier-like protein), signaling (phosphatidylinositol 3-related
kinase, protein kinase putative and protein-tyrosine phosphatase 1-like protein) and vesicular
trafficking (ras-related protein RAB1).
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Figure 3. Correlation between SNVs and PMM resistance: (a) Chromosomal distribution and correlation of SNV allele
frequency and PMM resistance. The X and Y axis correspond, respectively, to the chromosome position of each SNV and its
correlation to the PMM resistance phenotype. Significant correlations are represented by orange dots. SNVs with strong
significant positive or negative correlations (correlation coefficients r 0.7 and r ≤ −0.7) are represented by red dots.
(b) Pearson correlation plots of the 11 significant SNVs with strong correlation to PMM resistance. The box title contains the
SNV chromosome, position and correlation, r. The color of the dots reflects the level of resistance of the individual clones to
PMM, where yellow, grey and purple correspond respectively to RI < 2, 2 < RI < 5 and RI > 5.
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Figure 4. Correlation between gene CNVs and PMM resistance. Pearson correlation plots of the 39 significant genes with strong correlations to PMM resistance. The title for each box
contains the TriTrypDB gene ID and r correlation. The color of the dots reflects the clone’s resistance to PMM, where yellow, grey and purple correspond respectively to RI < 2, 2 < RI < 5
and RI > 5.
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Table 2. Genes potentially associated with PMM resistance. Correlation between gene copy number and PMM resistance.
Only genes for which the correlation, r, was ≥0.7 or ≤−0.7 and the correlation p-values were lower than 0.05 are reported.
GeneID: TriTrypDB L donovani gene ID; Chr: chromosome number; Pos 1: gene initial coordinate; Pos 2: gene final
coordinate; Correlation: Gene CN and PMM resistance correlation; p: Correlation p-value; Max: Maximum gene CN in all
clone/population; Min: Minimum gene CN in all clone/population; Max–Min: the difference between the Max and Min
gene CNV values.
Gene ID Chr Pos1 Pos2 Gene Annotation Correlation p Max Min Max − Min
LdBPK_020370.1 chr02 171561 171713
hypothetical protein unknown
function
0.73 4.96 × 10−3 2.09 0.88 1.21
LdBPK_070160.1 chr07 67067 67567 hypothetical protein conserved 0.73 4.54 × 10−3 1.21 0.73 0.48
LdBPK_070980.1 chr07 404916 406232 hypothetical protein conserved 0.74 3.96 × 10−3 1.13 0.85 0.28
LdBPK_141050.1 chr14 424294 425424
ADP/ATP mitochondrial
carrier-like protein
0.76 2.45 × 10−3 1.52 1.18 0.34
LdBPK_180600.1 chr18 242208 242483 hypothetical protein 0.76 2.47 × 10−3 1.15 0.77 0.38
LdBPK_230470.1 chr23 162446 163672 aldose 1-epimerase-like protein 0.71 6.97 × 10−3 1.54 1.31 0.23
LdBPK_250660.1 chr25 217458 219455 predicted zinc finger protein 0.76 2.84 × 10−3 1.17 0.96 0.21
LdBPK_250800.1 chr25 276286 277551
hypothetical protein unknown
function
0.77 2.10 × 10−3 1.09 0.89 0.2
LdBPK_270620.1 chr27 239023 239625
ras-related protein RAB1A
putative
0.76 2.58 × 10−3 1.3 0.78 0.52
LdBPK_271080.1 chr27 441116 442363 RING-H2 zinc finger putative 0.76 2.47 × 10−3 1.13 0.88 0.25
LdBPK_271370.1 chr27 539921 540925
proteasome regulatory
non-ATP-ase subunit 3 putative
0.70 7.57 × 10−3 1.26 0.84 0.42
LdBPK_271520.1 chr27 591692 592333
Eukaryotic translation initiation
factor 4E−1
0.71 6.85 × 10−3 1.15 0.89 0.26
LdBPK_271540.1 chr27 607146 609893
BRO1-like domain/ALIX
V-shaped domain binding to HIV
putative
0.75 3.40 × 10−3 1.19 0.96 0.23
LdBPK_280530.1 chr28 180433 182571 TPR repeat putative 0.72 5.12 × 10−3 1.06 0.87 0.19
LdBPK_280600.1 chr28 209904 211604
major surface protease gp63
putative
0.72 5.67 × 10−3 1.02 0.86 0.16
LdBPK_280630.1 chr28 222510 224015
hypothetical protein unknown
function
0.75 3.31 × 10−3 1.06 0.9 0.16
LdBPK_301200.1 chr30 387893 388444 hypothetical protein conserved 0.76 2.82 × 10−3 1.04 0.82 0.22
LdBPK_302290.1 chr30 855859 857973
tubulin-tyrosine ligase-like
protein
0.81 8.65 × 10−4 1.08 0.88 0.2
LdBPK_302310.1 chr30 864017 867931 hypothetical protein conserved 0.74 3.75 × 10−3 1.02 0.9 0.12
LdBPK_302740.1 chr30 1031040 1032266 TPR domain protein conserved 0.73 4.95 × 10−3 1 0.84 0.16
LdBPK_321520.1 chr32 572415 582050
phosphatidylinositol 3-related
kinase putative
0.88 7.93 × 10−5 1.02 0.93 0.09
LdBPK_330670.1 chr33 209670 210923
intraflagellar transport protein
57/55 putative
0.71 6.32 × 10−3 1.44 1.2 0.24
LdBPK_330890.1 chr33 292053 294803
hypothetical protein unknown
function
0.76 2.47 × 10−3 1.45 1.25 0.2
LdBPK_151060.1 chr33 429431 429940 60S ribosomal protein L6 putative 0.71 6.78 × 10−3 1.36 0.98 0.38
LdBPK_331560.1 chr33 594808 595194 RNA-binding protein putative 0.78 1.70 × 10−3 1.58 1.21 0.37
LdBPK_332810.1 chr33 1086018 1089704 hypothetical protein conserved 0.71 7.02 × 10−3 1.43 1.25 0.18
LdBPK_332950.1 chr33 1165769 1167190
transcription elongation
factor-like protein
0.71 6.23 × 10−3 1.49 1.24 0.25
LdBPK_341840.1 chr34 802817 803974 protein kinase putative 0.72 5.11 × 10−3 1.04 0.8 0.24
LdBPK_343220.1 chr34 1362570 1364477
DNA topoisomerase IB large
subunit
0.78 1.48 × 10−3 1.02 0.84 0.18
LdBPK_343390.1 chr34 1417106 1417627
Complex 1 protein (LYR family)
putative
0.74 4.04 × 10−3 1.09 0.81 0.28
LdBPK_361330.1 chr36 475562 475984 hypothetical protein (fragment) 0.86 1.79 × 10−4 0.52 0.27 0.25
LdBPK_361780.1 chr36 673858 675498 hypothetical protein conserved 0.88 8.22 × 10−5 1.12 0.89 0.23
LdBPK_362310.1 chr36 878592 880163
protein-tyrosine phosphatase
1-like protein
0.73 4.69 × 10−3 1.02 0.9 0.12
LdBPK_241390.1 chr24 496214 498880 hypothetical protein conserved −0.80 1.13 × 10−3 1.27 0.94 0.33
LdBPK_261490.1 chr26 541997 546778
hypothetical protein unknown
function
−0.72 5.61 × 10−3 1.65 1.37 0.28
LdBPK_261660.1 chr26 599794 600579 hypothetical protein conserved −0.79 1.19 × 10−3 1.61 1.25 0.36
LdBPK_291180.1 chr29 429699 429965
ribosomal protein L1aputative
(fragment)
−0.81 7.78 × 10−4 1.25 0.89 0.36
LdBPK_300440.1 chr30 142693 144375
quiescin sulfhydryl oxidase
putative
−0.72 5.96 × 10−3 1 0.81 0.19
LdBPK_363720.1 chr36 1394227 1395405 phytoene synthase putative −0.79 1.33 × 10−3 1.06 0.79 0.27
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4. Discussion
Although PMM resistance mechanisms are well-established for bacteria [28,29], sev-
eral hypotheses have been postulated for Leishmania, such as interference with ribosomal
protein synthesis and inhibition of respiration [11,30–35]. However, no genetic resistance
markers have been identified as yet. To try to identify these markers, the present study
performed whole genome sequencing and comparison of 12 amastigote-selected clones
and the pre-selection population, that had a large range of PMM resistances (Table 1).
Consistent with previous analyses, we were not able to identify a specific genetic change
that unequivocally explains PMM resistance. While the 12 post-selection clones contained
numerous new SNV mutations that were fixed in all post-selection clones, these common
mutations cannot explain the large variation in PMM resistance within these clones. As
clone IC50 values range from 57 µM (only marginally greater than the pre-selection strain
at 45 µM) to 417 µM, we hypothesized that multiple other non-fixed genetic differences
contribute to PMM resistance. To determine which of these genetic differences may be
associated with resistance, we compared within-clone allele frequencies, gene CNV and
chromosome CNV with PMM resistance, using a similar approach to the genome-wide
association study (GWAS) approach.
The majority of the SNV positions whose within-clone allele frequency correlated with
PMM resistance were observed in intergenic regions, including notably two upstream of
the chaperone DnaJ protein and aspartate aminotransferase genes. Aspartate aminotransferase
has been described to be significantly elevated in patients receiving PMM, indicating
hepatotoxicity or another drug effect [36]. Further, only two synonymous SNPs were
identified within genes, in HSP78 and sterol 24-c-methyltransferase. Although synonymous
mutations are often not phenotypically relevant, they may affect translation by differences
in codon usage. Both affected genes are of potential relevance to PMM resistance, as the
HSP78 gene in L. donovani is an important virulence factor, needed to suppress immune
activation and escape from NO-mediated toxicity in macrophages [37], whereas sterol 24-c-
methyltransferase in L. major has been linked to mitochondrial function and virulence [38].
For both genes, a negative correlation was found between the alternate allele frequency and
PMM resistance. The lower relative synonymous codon usage of the alternate codon in the
HSP78 gene (RSCU decrease from 1.439 to 1.115 for UCG → UCC) would indicate a higher
expression to be linked to PMM resistance. A negative correlation was also found for sterol
24-c-methyltransferase alternate allele frequency and the PMM IC50 values. The reduced
frequency of the alternate codon (codon UUC → UUU, RSCU decrease from 1.28 to 0.72)
is anticipated to decrease the expression levels in favor of increased resistance. Genomic
instability of sterol 24-c-methyltransferase has already been associated with amphotericin B
resistance in L. mexicana, L. major, L. donovani and L. infantum [39,40]. In this study, however,
no correlation could be demonstrated between the PMM resistance profiles of the different
clones and their susceptibility towards amphotericin B. In a study with promastigote-
selected PMM-resistant lines, no differential expression of sterol 24-c-methyltransferase was
noted [40], but it should be mentioned that in these strains, PMM susceptibility of the
amastigote stage remained unaltered [12,41], whereas selection on the amastigote level
triggers a completely different outcome [9].
Despite stability of the PMM resistance upon parasite passage in mice or sand
flies [9,42], suggesting a stable genomic modification, this comparison mostly identified
gene CNVs correlating with resistance. Chromosomal somy changes could not be un-
equivocally correlated to the variable PMM susceptibility of the different clones. Due to
the extremely high genome plasticity of Leishmania, somy changes should be cautiously
interpreted, as they are readily affected by culture conditions, prolonged cultivation and
the associated virulence changes [43]. Nonetheless, the CNV of 39 genes was found to be
statistically associated with PMM resistance, where 33 were a result of gene expansions and
6 of gene losses. While 14 of these code for hypothetical proteins, the other 25 are known to
be involved in transcription, translation and protein turn-over, virulence, mitochondrial
function, signaling and vesicular trafficking. Although the exact mechanisms of action
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of PMM in Leishmania are yet to be elucidated, past research on experimentally selected
resistant L. donovani already suggested that PMM not only impairs protein synthesis and
modifies membrane fluidity and permeability, but also causes respiratory dysfunction with
associated alterations of the mitochondrial membrane potential [11,32,35,40,44–46].
When only considering those genes with a copy number difference amplitude of
at least 0.3 haploid genome copies, 11 genes could be identified, of which 6 have been
annotated (i.e., ADP/ATP mitochondrial carrier-like protein, ras-related protein RAB1, 60S
ribosomal protein L6, proteasome regulatory non-ATP-ase subunit 3, an RNA-binding protein
and ribosomal protein L1a). ADP/ATP mitochondrial carrier-like proteins are known to
transfer molecules across mitochondrial membranes [47] and could therefore potentially
play a role in drug transport into a main target organelle. The Ras-related protein RAB1
is involved in vesicular trafficking and is a known regulator of secretory pathways of
several important Leishmania virulence factors, including gp63 and acid phosphatase [48].
Proteasome regulatory non-ATP-ase subunit 3 is important in the regulation of proteosomal
functions, of which inhibition hampers specific stages of morphological differentiation
in various protozoan parasites, including Leishmania [49]. In L. infantum, proteasomal
functions were shown to be essential for replication and intracellular survival of amastigotes
in the host cell [50]. Its upregulation upon PMM selection thus supports the increased
intracellular parasite fitness observed by our group and others [12,43,51]. The increased
virulence may also relate to the detected CNVs for the virulence genes major surface protease
gp63 and protein-tyrosine phosphatase 1-like protein [52]. The identification of the ribosomal
protein L6 gene is also noteworthy as it has been shown to be involved in bacterial resistance
against aminoglycosides in the past [53]. Moreover, its close homologue, the 60s ribosomal
protein L23, is known to be overexpressed in antimony-resistant parasites [54]. Additionally,
RNA-binding protein overexpression has already been described in antimony-resistant
strains [55], and could be linked to an increased parasite replication efficacy [56]. A negative
correlation was found for the ribosomal protein L1a and quiescin sulfhydryl oxidase. Although
not much information can be found in the literature on the role of both gene products in
antileishmanial drug resistance, quiescin sulfhydryl oxidase has been associated with the
induction of reduced cell proliferation and quiescence, for example in fibroblasts [57,58].
Its decreased expression may increase cell proliferation, which in theory fits the increased
parasite fitness observed for PMM-resistant parasites [12]. Finally, the presence of several
hypothetical proteins in which gene copy number alteration was potentially associated with
PMM resistance reinforces the importance of characterizing unknown protein functions
in Leishmania.
Other research groups have evaluated PMM resistance markers using genomic,
metabolomic or transcriptomic comparisons [43,44,59]. Metabolic and lipidomic changes
were shown to be strain-specific [43], and up until now, no suitable PMM resistance
biomarkers have been identified. None of the post-selection variants that we found to be
associated with PMM resistance were previously identified by earlier research as associated
with Leishmania’s PMM resistance. However, this is not completely unexpected as the
present study was the only one to have selected PMM resistance directly on intracellular
amastigotes. Our results indicate the likely multifactorial nature of PMM resistance, which
complicates the identification of a single genetic marker for application in clinical settings.
In-depth research and validation of the identified genetic variations in a range of clinical
isolates will be necessary to understand their biological importance and use as potential
resistance markers.
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